Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.

The trial will include patients with non-small cell lung, colorectal, head and neck, and cutaneous cancers with EGFR amplification.

Blood Cancer UK is launching early career grants following a tough pandemic-era funding climate, while US funders worry about federal cuts.

The reorganization and pipeline prioritization is expected to extend the company's operational runway into 2027 and support its long-term growth.